The identification of patients presenting with a demyelinating syndrome that does not fulfill contemporaneous diagnostic criteria for multiple sclerosis ("Clinically Isolated Syndrome (CIS)") 1 yet who will subsequently develop multiple sclerosis (MS) is of consequence. Early initiation of disease modifying therapies (DMTs) in such patients may prevent disability. 2 As a result, research concerning MS diagnosis over the past 20 years has focused on cohorts comprising patients diagnosed with MS, who initially presented with CIS. Revisions to the McDonald Criteria based on this research have allowed for earlier diagnosis of MS in an increasing proportion of patients who would have been diagnosed with CIS by prior criteria. These revisions have maintained good sensitivity and specificity for MS in subsequent validation studies. Recent revisions to the 2017 McDonald Criteria 1 likewise were based upon studies comprised of historical cohorts of patients presenting with CIS, 3 and may increase sensitivity for MS even further. 4 Ongoing diagnostic research in MS continues to refine the performance of McDonald Criteria in CIS cohorts. 5 In spite of iterative revisions to McDonald Criteria, the misdiagnosis of MS (the incorrect assignment of a MS diagnosis) remains a frequent and persistent contemporary problem. 2 Patients misdiagnosed with MS receive inadequate treatment for their correct diagnoses and suffer unnecessary risks and morbidities due to a misdiagnosis, sometimes for decades. Misdiagnosed patients have even participated in clinical trials for MS therapeutics. MS misdiagnosis also results in potentially enormous unnecessary cost to healthcare systems. 2 In recent research presented at the 2018 European Committee for Treatment and Research in Multiple Sclerosis Annual Congress (Kaisey et al, Poster P656, Session 2, 11 October 2018), 18% of patients referred to two academic MS centers over the course of just 1 year with a previously established diagnosis of MS, were subsequently found not to have MS.
Why does misdiagnosis remain a problem in spite of continual refinement of MS diagnostic criteria? The CIS cohorts that have informed revisions to McDonald Criteria were recruited at academic MS subspecialty centers, where due to referral bias, they already have a high likelihood of MS. MS specialists at such centers also have expert skill for the identification of monophasic syndromes typical of MS-related demyelination required for application of the McDonald Criteria, including CIS. The latter is perhaps the crux of the problem. As authors of the 2017 revisions emphasize, 1 the McDonald Criteria are not meant to serve as a screening tool to identify CIS or MS among the many patients who present to "real world" neurology clinics with any variety of neurological symptoms, exam findings, or magnetic resonance imaging (MRI) abnormalities that may raise concern for MS. McDonald Criteria only perform well when they are appropriately applied, and this relies on knowledge of all of its details and caveats and skillful navigation of successive clinical judgments by the evaluating neurologist. The evaluating neurologist's assessment serves as the initial "screening tool" that must ensure that the patient's clinical presentation is appropriate for application of McDonald Criteria before fulfillment of its elements is assessed.
The clinical and radiographic assessments that comprise the McDonald Criteria are susceptible to error. The fundamental initial assessment for application of the criteria to proceed-confirmation of objective evidence of a syndrome typical of MS-demyelinationis often challenging. For instance, numerous syndromes may mimic optic neuritis 6 or transverse myelitis. In addition, patients misdiagnosed with MS frequently present with syndromes atypical for MS, or had red flags suggesting alternative diagnoses. Although the application of McDonald Criteria should not proceed in such patients, overreliance on MRI abnormalities in patients with syndromes in which the criteria were never evaluated is frequently associated with MS misdiagnosis. Some patients misdiagnosed with MS were found to never have fulfilled either the clinical or the radiographic elements of McDonald Criteria. Some patients misdiagnosed with MS in the aforementioned study by Kaisey et al had a normal brain MRI.
Further research focused on tweaking McDonald Criteria that relies on CIS cohorts, therefore, is unlikely to ameliorate the problem of MS misdiagnosis. Revisions to the McDonald Criteria will not prevent their inexpert application or the inaccurate identification of typical syndromes. Furthermore, particularly with incorporation of positive cerebrospinal fluid (CSF) oligoclonal bands as a substitute for DIT in 2017, further refinement of McDonald Criteria may only effect small gains in sensitivity that are at the expense of specificity-a concern raised by an initial study evaluating the 2017 Criteria. 4 Finally, tweaking McDonald Criteria further in CIS cohorts will neither aid in the confirmation of a diagnosis in patients with MS who initially present with atypical syndromes, nor confirm the accuracy of an MS diagnosis in the considerable number of patients who present with a long-standing pre-existing diagnosis of MS after changing providers, as it was not developed for use in these populations.
What is indeed needed are screening tools and criteria that distinguish MS from other conditions that minimize the need for, and number of, clinical judgments by providers to both prevent misdiagnoses and accurately diagnose MS earlier. Such an approach would optimize the use of objective and automated laboratory and/or imaging biomarkers. Research focused on biomarkers for MS diagnosis remains an area of unmet and pressing need, particularly given the likely magnitude of MS misdiagnosis. Yet this problem has been the focus of relatively little scientific inquiry compared to prognostication or therapeutics in MS. For instance, at the 2017 European Committee for Treatment and Research in Multiple Sclerosis Annual Congress, only 3% of the 1757 research abstracts presented focused on either diagnosis or differential diagnosis.
Over the past few decades, numerous candidate MS biomarkers have proven disappointing in subsequent validation studies, which may have tempered enthusiasm for diagnostic biomarker research. However, as MS research enters the era of "precision medicine" and our understanding of the pathological processes underlying this disease has advanced, novel approaches are now possible. For instance, advanced imaging techniques demonstrating the perivenous location of MS lesions (the "central vein sign") 7 and laboratory assays evaluating expression of serum microRNAs and lipids in MS patients 8, 9 have raised hope for their use as successful diagnostic biomarkers. Methods such as machine learning may aid in the identification of both diagnostic thresholds 9 and automated tools 10 to facilitate translation to clinical application.
Given the heterogeneity of MS, ultimately a multimodal approach that combines several candidate laboratory and imaging methods may be required to develop a diagnostic criteria with optimal specificity. After cross-sectional studies show promise, what is needed, rather than further tweaking of the diagnostic criteria for MS in those with CIS, are validation studies of promising diagnostic biomarkers in prospective multicenter studies comprising "real world" patients referred for the evaluation of a diagnosis of MS.
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The author(s) received no financial support for the research, authorship, and/or publication of this article. 3 This latest set of changes has the potential to streamline the diagnostic process in people with suspected MS, increasing the number of patients diagnosed at the time of disease onset rather than requiring follow-up MRI scans, or a second clinical attack. 4 However, nearly half of people with MS are unable to be diagnosed at the time of presentation, even when applying the most up-to-date revisions to the McDonald criteria. 4 It seems likely that there will be further changes to the diagnostic criteria for MS in the future as new evidence becomes available. For example, a recent study found that including optic nerve lesions (detected clinically and/or with visual evoked potential testing)
